---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-101447"
form_type: "8-K"
ticker: "ARMP"
cik: "0000921114"
company_name: "Armata Pharmaceuticals, Inc."
filed_at: "2025-10-22T23:59:59+00:00"
generated_at: "2026-05-17T02:55:23.390858+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Armata AP-SA02 phage cocktail hits primary endpoint in Phase 2a S. aureus bacteremia trial

## Summary
- Day 12 clinical response 88% AP-SA02 vs 58% placebo (p=0.047) by blinded investigators; 83% vs 58% by adjudication committee.
- Zero non-response/relapse in AP-SA02 arm at one week post-BAT and EOS vs ~25% placebo (p<0.025).
- AP-SA02 well-tolerated; no serious adverse events related to study drug; TEAEs 6% AP-SA02 vs 0% placebo.
- Armata plans to initiate a pivotal Phase 3 superiority trial in 2026, subject to FDA feedback.
- Defined phage variants in AP-SA02 show intrinsic adaptive mechanism to patient isolates, may enhance efficacy.

## SEC filing metadata
- accession: 0001104659-25-101447
- form_type: 8-K
- ticker: ARMP
- cik: 0000921114
- company_name: Armata Pharmaceuticals, Inc.
- filed_at: 2025-10-22T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/921114/000110465925101447/0001104659-25-101447-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/921114/000110465925101447/tm2529060d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-101447
- JSON: https://secwatch.observer/filing/0001104659-25-101447.json
- Plain text: https://secwatch.observer/filing/0001104659-25-101447.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.